pancreatic cancer
Conditions
Interventions
Gold Standard:NCCN
Index test:Targeted pancreatic cancer susceptibility gene sequencing panel design
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Patients with pancreatic cancer should meet the following criteria to be enrolled in the trial: 1. age =18 and =90 years with pancreatic cancer, regardless of gender; 2. Peripheral blood can be obtained; 3. ECOG 0~2 points; 4. Subjects voluntarily participate and sign the informed consent; 5. No serious hematologic, cardiac, pulmonary functional abnormalities and immunodeficiencies (refer to the respective criteria); 6. Ability to comply with the study visit plan and other protocol requirements. High-risk individuals should meet the following criteria to be enrolled in the trial: 1. Presence of known pancreatic cancer susceptibility genes such as ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, EPCAM, PALB2, STK11, TP53 and other pathogenic and/or probable germline mutations, as well as the presence of a family history of pancreatic cancer (first-degree or second-degree relatives) associated with germline pathogenic or probable pathogenic mutations; 2. People with 2 or more first-degree relatives in the family with pancreatic (even in the absence of a known pathogenic/probably pathogenic germline mutation); 3. People with a family history of pancreatic cancer in 3 or more first- (or) second-degree relatives (even in the absence of a known pathogenic/probably pathogenic germline variant).
Exclusion criteria
Exclusion criteria: 1. The histologic pattern does not meet the pathological diagnostic criteria of pancreatic ductal adenocarcinoma; 2. Any other medical conditions and social/psychological problems, etc., which are judged by the investigator to be unsuitable for participation in the initial collection of information on the enrolled population.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive predictive value;Negative expected value;specificity;sensitiveness;consistence;Kappa value; | — |
Countries
China
Contacts
Public ContactYu Xianjun
Fudan University Shanghai Cancer Center
Outcome results
None listed